Ramelyte, Egle; Nägeli, Mirjam C; Hunger, Robert; Merat, Rastine; Gaide, Olivier; Navarini, Alexander A; Cozzio, Antonio; Wagner, Nikolaus B; Maul, Lara Valeska; Dummer, Reinhard (2023). Swiss Recommendations for Cutaneous Basal Cell Carcinoma. Dermatology, 239(1), pp. 122-131. Karger 10.1159/000526478
|
Text
Swiss_recommendations.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (321kB) | Preview |
Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer in Switzerland and worldwide. Most BCCs can be treated in a curative setting. However, patients can develop locally destructive and, rarely, metastatic tumors that require a different treatment approach. The clinical subtype of individual lesions provides prognostic information and influences management decisions. Surgical excision, topical therapies, and radiotherapy are highly effective in the majority of subtypes as well as in low- and high-risk diseases. For patients with low-risk diseases and superficial tumors not amenable to surgery, several nonsurgical alternatives are available. Systemic therapy is indicated for high-risk BCCs, which are not amenable to either surgery or radiotherapy. Hedgehog pathway inhibitors (HHI) are currently approved. Other therapeutic options such as immune checkpoint inhibitors show promising results in clinical trials. This first version of Swiss recommendations for diagnosis and management of BCC was prepared through extensive literature review and an advisory board consensus of expert dermatologists and oncologists in Switzerland. The present guidelines recommend therapies based on a multidisciplinary team approach and rate of recurrence for individual lesions. Based on the risk of recurrence, two distinct groups have been identified: low-risk (easy-to-treat) and high-risk (difficult-to-treat) tumors. Based on these classifications, evidence-based recommendations of available therapies are presented herein.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Hunger, Robert |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1018-8665 |
Publisher: |
Karger |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
26 Sep 2022 12:36 |
Last Modified: |
21 Jan 2023 00:13 |
Publisher DOI: |
10.1159/000526478 |
PubMed ID: |
36137524 |
Uncontrolled Keywords: |
Basal cell carcinoma Hedgehog pathway inhibitors Locally advanced tumor Metastatic tumor PD-1 inhibitors |
BORIS DOI: |
10.48350/173208 |
URI: |
https://boris.unibe.ch/id/eprint/173208 |
Actions (login required)
 |
Edit item |